who's who

5 Houston innovators headed to SXSW to know this weekend

Meet five of the many Houston innovators that will be out at SXSW Pitch, Houston House, Founded in Texas, and much more this week and into next week. Photos courtesy

Editor's note: It's a special Friday edition of innovators to know this week — well, weekend. SXSW kicks off today and Houstonians will be headed up to Austin for the week or just the weekend. If you're looking out for the best panels and talks to go to, look no further than this guide I created — as well as the five Houston innovators I think you should know who are listed below.

Lara Cottingham, chief of staff for Greentown Labs

Photo via LinkedIn

Calling all energy transition startups, investors, and more. The Greater Houston Partnership is hosting a full day of energy transition discussions at Houston House on Monday, March 14, at the Line Hotel. Lara Cottingham of Greentown Labs will be at the activation site with a must-attend networking hour at 4 pm called Transition on Tap.

Diana Murakhovskaya, co-founder and general partner of The Artemis Fund

Photo via LinkedIn

Who runs the world? Women. And Diana Murakhovskaya knows that based off her work with her Houston-based venture capital fund, The Artemis Fund. Project W, Artemis Fund, HearstLab, and Beam have teamed up at SXSW to present the second Founded in Texas event on Sunday, March 13, at Relay Coworking. Twelve founders selected by application will pitch to investors from across the country . The audience will get a glimpse of the innovation and creativity at work in the growing Texas startup ecosystem.

Pamela Singh, co-founder and CEO of CaseCTRL

Photo courtesy of CaseCTRL

Pamela Singh is the only Houston startup founder to pitch this year at SXSW's pitch competition. Representing her digital health startup, Case CTRL, Singh takes the prestigious stage Saturday, March 12, to compete in the Enterprise & Smart Data Technology category.

Sandy Guitar, managing director of HX Venture Fund

Photo courtesy of Sandy Guitar

The HX Venture Fund is hosting a meetup that all of the Houston startup ecosystem needs to know about. Network with a number of founders from Houston's fastest-growing startups along with several great VCs around the nation to participate in a joint conversation about founding tech startups. The event will take place at 11:30 am to 12:30 pm at Hilton Austin Downtown, Room 408.

Ashley DeWalt, managing director of DivInc

Photo courtesy of DivInc

Ashley DeWalt, managing director of DivInc, is just one of the many Houston innovators featured in Houston House from the GHP. The activation starts Sunday, March 13, at the Line Hotel with a day of programming across industries and topics — from sports tech and diversity (both topics DeWalt specializes in) to health care innovation and space. Catch DeWalt's panel, Game Changers - The Rise of Sports Tech, on Sunday at 11:30 am at Houston House.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted